Antioxidant protection and neurodegenerative disease: The role of amyloid-β and tau

American Journal of Alzheimer's Disease and other Dementias

Volumn 21, Issue 2, 2006, Pages 126-130

  Castellani, Rudy J ^a   Lee, Hyoung Gon ^b   Perry, George ^b   Smith, Mark A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Antioxidant; Free radical; Phosphorylation; Redox active metals; Tau

Indexed keywords

AMYLOID BETA PROTEIN; FREE RADICAL; METAL; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG TARGETING; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; SENILE PLAQUE;

EID: 33645775687     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750602100213     Document Type: Article

References (68)

1. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991; 82: 239-259.
2. Mirra SS, Heyman A, McKeel D, et al.: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41: 479-486.
3. Selkoe DJ: Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001; 3: 75-80.
4. Roizen NJ, Patterson D: Down's syndrome. Lancet. 2003; 361: 1281-1289.
5. Knowles RB, Gomez-Isla T, Hyman BT: Abeta associated neuropil changes: Correlation with neuronal loss and dementia. J Neuropathol Exp Neurol. 1998; 57: 1122-1130.
6. Smith MA, Joseph JA, Perry G: Arson. Tracking the culprit in Alzheimer's disease. Ann N Y Acad Sci. 2000; 924: 35-38.
7. Nunomura A, Perry G, Pappolla MA, et al.: Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol. 2000; 59: 1011-1017.
8. Nunomura A, Perry G, Aliev G, et al.: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001; 60: 759-767.
9. Yan SD, Yan SF, Chen X, et al.: Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med. 1995; 1: 693-699.
10. Tamagno E, Parola M, Bardini P, et al.: Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem. 2005; 92: 628-636.
11. van Groen T, Puurunen K, Maki HM, et al: Transformation of diffuse beta-amyloid precursor protein and beta-amyloid deposits to plaques in the thalamus after transient occlusion of the middle cerebral artery in rats. Stroke. 2005; 36: 1551-1556.
12. Cuajungco MP, Goldstein LE, Nunomura A, et al.: Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem. 2000; 275: 19439-19442.
13. Davis DG, Schmitt FA, Wekstein DR, et al.: Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999; 58: 376-388.
14. Pike CJ, Walencewicz AJ, Glabe CG, et al.: Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol. 1991; 207: 367-368.
15. Huang X, Cuajungco MP, Atwood CS, et al.: Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999; 274: 37111-37116.
16. Boyd-Kimball D, Sultana R, Abdul HM, et al.: Gamma-glutamyl-cysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. J Neurosci Res. 2005; 79: 700-706.
17. Boyd-Kimball D, Sultana R, Poon HF, et al.: Gamma-glutamyl-cysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: A proteomics approach. J Neurosci Res. 2005; 79: 707-713.
18. Rottkamp CA, Raina AK, Zhu X, et al.: Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med. 2001; 30: 447-450.
19. Frautschy SA, Cole GM, Baird A: Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol. 1992; 140: 1389-1399.
20. Canning DR, McKeon RJ, DeWitt DA, et al.: Beta-amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp Neurol. 1993; 124:289-298.
21. DeWitt DA, Perry G, Cohen M, et al.: Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol. 1998; 149: 329-340.
22. Walter MF, Mason P, Mason RP: Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Biochem Biophys Res Commun. 1997; 233: 760-764.
23. Davies L, Wolska B, Hilbich C, et al.: A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988; 38: 1688-1693.
24. McLean CA, Cherny RA, Fraser FW, et al.: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999; 46: 860-866.
25. Xia W, Zhang J, Kholodenko D, et al.: Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997; 272: 7977-7982.
26. Walsh DM, Klyubin I, Fadeeva JV, et al.: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416: 535-539.
27. Walsh DM, Townsend M, Podlisny MB, et al.: Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005; 25: 2455-2462.
28. Joseph JA, Shukitt-Hale B, Denisova NA, et al.: Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci. 1998; 18: 8047-8055.
29. Joseph JA, Shukitt-Hale B, Denisova NA, et al.: Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci. 1999; 19: 8114-8121.
30. Bickford PC, Gould T, Briederick L, et al.: Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. Brain Res. 2000; 866: 211-217.
31. Casadesus G, Shukitt-Hale B, Stellwagen HM, et al.: Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. Nutr Neurosci. 2004; 7: 309-316.
32. Lee HG, Perry G, Moreira PI, et al.: Tau phosphorylation in Alzheimer's disease: Pathogen or protector? Trends Mol Med. 2005; 11: 164-169.
33. Takeda A, Perry G, Abraham NG, et al.: Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J Biol Chem. 2000; 275: 5395-5399.
34. Long JM, Mouton PR, Jucker M et al.: What counts in brain aging? Design-based stereological analysis of cell number. J Gerontol A Biol Sci Med Sci. 1999; 54: B407-417.
35. Hsiao K, Chapman P, Nilsen S, et al.: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 274: 99-102.
36. Pappolla MA, Chyan YJ, Omar RA, et al.: Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: A chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol. 1998; 152: 871-877.
37. Smith MA, Hirai K, Hsiao K, et al.: Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 1998; 70: 2212-2215.
38. Pratico D, Uryu K, Leight S, et al.: Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001; 21: 4183-4187.
39. Smith MA, Kutty RK, Richey PL, et al.: Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol. 1994; 145: 42-47.
40. Mori H, Kondo J, Ihara Y: Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science. 1987; 235: 1641-1644.
41. Perry G, Friedman R, Shaw G, et al.: Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A. 1987; 84: 3033-3036.
42. Calhoun ME, Wiederhold KH, Abramowski D, et al.: Neuron loss in APP transgenic mice. Nature. 1998; 395: 755-756.
43. Joseph J, Shukitt-Hale B, Denisova NA, et al.: Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging. 2001; 22: 131-146.
44. Gordon MN, King DL, Diamond DM, et al.: Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001; 22: 377-385.
45. Gomez-Isla T, Hollister R, West H, et al.: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997; 41: 17-24.
46. Kril JJ, Patel S, Harding AJ, et al.: Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (Berl). 2002; 103: 370-376.
47. Nunomura A, Perry G, Pappolla MA, et al.: RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 1999; 19: 1959-1964.
48. Smith MA, Rudnicka-Nawrot M, Richey PL, et al.: Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem. 1995; 64: 2660-2666.
49. Sayre LM, Zelasko DA, Harris PL, et al.: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 1997; 68: 2092-2097.
50. Liu Q, Smith MA, Avila J, et al.: Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med. 2005; 38: 746-754.
51. Takeda A, Smith MA, Avila J, et al.: In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem. 2000; 75: 1234-1241.
52. Calingasan NY, Uchida K, Gibson GE: Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease. J Neurochem. 1999; 72: 751-756.
53. Morsch R, Simon W, Coleman PD: Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol. 1999; 58: 188-197.
54. Wataya T, Nunomura A, Smith MA, et al.: High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem. 2002; 277: 4644-4648.
55. Zhu X, Rottkamp CA, Boux H, et al.: Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000; 59: 880-888.
56. Zhu X, Rottkamp CA, Hartzler A, et al.: Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem. 2001; 79: 311-318.
57. Zhu X, Castellani RJ, Takeda A, et al.: Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: The 'two hit' hypothesis. Mech Ageing Dev. 2001; 123: 39-46.
58. Zhu X, Raina AK, Rottkamp CA, et al.: Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001; 76: 435-441.
59. Castellani R, Smith MA, Richey PL, et al.: Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res. 1995; 696: 268-271.
60. Odetti P, Garibaldi S, Norese R, et al.: Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2000; 59: 393-397.
61. Gerst JL, Siedlak SL, Nunomura A, et al.: Role of oxidative stress in frontotemporal dementia. Dement Geriatr Cogn Disord. 1999; 10 Suppl 1: 85-87.
62. Ekinci FJ, Shea TB: Phosphorylation of tau alters its association with the plasma membrane. Cell Mol Neurobiol. 2000; 20: 497-508.
63. Arrasate M, Mitra S, Schweitzer ES, et al.: Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004; 431: 805-810.
64. Perry G, Nunomura A, Raina AK, et al.: Amyloid-beta junkies. Lancet. 2000; 355: 757.
65. Smith MA, Atwood CS, Joseph JA, et al.: Predicting the failure of amyloid-beta vaccine. Lancet. 2002; 359: 1864-1865.
66. Rottkamp CA, Atwood CS, Joseph JA, et al.: The state versus amyloid-beta: The trial of the most wanted criminal in Alzheimer disease. Peptides. 2002; 23: 1333-1341.
67. Smith MA, Casadesus G, Joseph JA, et al.: Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med. 2002; 33: 1194-1199.
68. Lee HG, Casadesus G, Zhu X, et al.: Challenging the amyloid cascade hypothesis: Senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci. 2004; 1019: 1-4.